Timeline: Expected Clinical Trial Readouts For PD-1 Competitors

Scrip highlights the top data readouts expected over the next 12 months from the big PD-1/PD-L1 players, such as Bristol Myers Squibb and Merck & Co. – as well as a few compounds to watch out for earlier in the cancer immunotherapy pipeline.

As we get over the hump of third-quarter financial reports, Scrip has taken a look at updates from the big PD-1/PD-L1 players, creating a handy calendar of key data readouts to watch for this winter and into 2017.

According to Informa Pharma Intelligence's Trialtrove database there are currently 904 ongoing clinical trials for immuno-oncology agents in the US and the top three most popular indications are

More from Clinical Trials

More from R&D